Dynavax Technologies (NASDAQ:DVAX) Share Price Crosses Above 200-Day Moving Average – Here’s What Happened

Dynavax Technologies Co. (NASDAQ:DVAX)’s share price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $11.62 and traded as high as $12.87. Dynavax Technologies shares last traded at $12.62, with a volume of 5,449,688 shares changing hands.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $29.00 target price on shares of Dynavax Technologies in a research report on Friday, November 8th.

Dynavax Technologies Price Performance

The firm has a market cap of $1.66 billion, a P/E ratio of 97.08 and a beta of 1.34. The firm’s 50 day moving average is $12.72 and its 200 day moving average is $11.62. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. GAMMA Investing LLC increased its holdings in Dynavax Technologies by 55.1% in the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock worth $52,000 after buying an additional 1,457 shares in the last quarter. Sanctuary Advisors LLC grew its stake in shares of Dynavax Technologies by 9.1% in the third quarter. Sanctuary Advisors LLC now owns 17,727 shares of the biopharmaceutical company’s stock worth $197,000 after acquiring an additional 1,484 shares during the period. Nisa Investment Advisors LLC raised its holdings in shares of Dynavax Technologies by 44.6% during the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 1,679 shares during the last quarter. US Bancorp DE lifted its position in Dynavax Technologies by 291.4% during the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,034 shares during the period. Finally, Parkman Healthcare Partners LLC lifted its position in Dynavax Technologies by 1.2% during the third quarter. Parkman Healthcare Partners LLC now owns 219,451 shares of the biopharmaceutical company’s stock valued at $2,445,000 after purchasing an additional 2,629 shares during the period. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.